Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and Sequence.

Nadai Y, Held K, Joseph S, Ahmed MIM, Hoffmann VS, Peterhoff D, Missanga M, Bauer A, Joachim A, Reimer U, Zerweck J, McCormack S, Cope AV, Tatoud R, Shattock RJ, Robb ML, Sandstroem EG, Hoelscher M, Maboko L, Bakari M, Kroidl A, Wagner R, Weber J, Pollakis G, Geldmacher C.

Front Immunol. 2019 Apr 24;10:717. doi: 10.3389/fimmu.2019.00717. eCollection 2019.

2.

Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions.

Moore CL, Stöhr W, Crook AM, Richert L, Leliévre JD, Pantaleo G, García F, Vella S, Lévy Y, Thiébaut R, McCormack S.

Lancet HIV. 2019 May;6(5):e334-e340. doi: 10.1016/S2352-3018(19)30082-7.

PMID:
31047670
3.

Intimate partner violence, depression, and sexual behaviour among gay, bisexual and other men who have sex with men in the PROUD trial.

Miltz AR, Lampe FC, Bacchus LJ, McCormack S, Dunn D, White E, Rodger A, Phillips AN, Sherr L, Clarke A, McOwan A, Sullivan A, Gafos M.

BMC Public Health. 2019 Apr 25;19(1):431. doi: 10.1186/s12889-019-6757-6.

4.

Predictive factors for HIV infection among men who have sex with men and who are seeking PrEP: a secondary analysis of the PROUD trial.

White E, Dunn DT, Desai M, Gafos M, Kirwan P, Sullivan AK, Clarke A, McCormack S; PROUD study group.

Sex Transm Infect. 2019 Mar 27. pii: sextrans-2018-053808. doi: 10.1136/sextrans-2018-053808. [Epub ahead of print]

5.

Getting pre-exposure prophylaxis (PrEP) to the people: opportunities, challenges and examples of successful health service models of PrEP implementation.

Zablotska IB, Baeten JM, Phanuphak N, McCormack S, Ong J.

Sex Health. 2018 Nov;15(6):481-484. doi: 10.1071/SH18182.

PMID:
30496716
6.

Meet the Editors.

Zablotska I, Baeten J, Phanuphak N, McCormack S, Ong J.

Sex Health. 2018 Nov;15(6):i-iii. doi: 10.1071/SHv15n6_MeetED. No abstract available.

PMID:
30496715
7.

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.

Viegas EO, Kroidl A, Munseri PJ, Missanga M, Nilsson C, Tembe N, Bauer A, Joachim A, Joseph S, Mann P, Geldmacher C, Fleck S, Stöhr W, Scarlatti G, Aboud S, Bakari M, Maboko L, Hoelscher M, Wahren B, Robb ML, Weber J, McCormack S, Biberfeld G, Jani IV, Sandström E, Lyamuya E; TaMoVac study group.

PLoS One. 2018 Nov 29;13(11):e0206838. doi: 10.1371/journal.pone.0206838. eCollection 2018.

8.

Protocol, rationale and design of SELPHI: a randomised controlled trial assessing whether offering free HIV self-testing kits via the internet increases the rate of HIV diagnosis.

Gabriel MM, Dunn DT, Speakman A, McCabe L, Ward D, Witzel TC, Harbottle J, Collins S, Gafos M, Burns FM, Lampe FC, Weatherburn P, Phillips A, McCormack S, Rodger AJ.

BMC Infect Dis. 2018 Oct 23;18(1):531. doi: 10.1186/s12879-018-3433-x.

9.

What happens when PrEP is scaled up? Results from EPIC-NSW.

McCormack S.

Lancet HIV. 2018 Nov;5(11):e607-e608. doi: 10.1016/S2352-3018(18)30253-4. Epub 2018 Oct 17. No abstract available.

PMID:
30343027
10.

The Context of Sexual Risk Behaviour Among Men Who Have Sex with Men Seeking PrEP, and the Impact of PrEP on Sexual Behaviour.

Gafos M, Horne R, Nutland W, Bell G, Rae C, Wayal S, Rayment M, Clarke A, Schembri G, Gilson R, McOwan A, Sullivan A, Fox J, Apea V, Dewsnap C, Dolling D, White E, Brodnicki E, Wood G, Dunn D, McCormack S.

AIDS Behav. 2019 Jul;23(7):1708-1720. doi: 10.1007/s10461-018-2300-5.

11.

Evolution of a pre-exposure prophylaxis (PrEP) service in a community-located sexual health clinic: concise report of the PrEPxpress.

Girometti N, McCormack S, Devitt E, Gedela K, Nwokolo N, Patel S, Suchak T, McOwan A, Whitlock G.

Sex Health. 2018 Nov;15(6):598-600. doi: 10.1071/SH18055.

PMID:
30249318
12.

Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.

Cheeseman HM, Day S, McFarlane LR, Fleck S, Miller A, Cole T, Sousa-Santos N, Cope A, Cizmeci D, Tolazzi M, Hwekwete E, Hannaman D, Kratochvil S, McKay PF, Chung AW, Kent SJ, Cook A, Scarlatti G, Abraham S, Combadiere B, McCormack S, Lewis DJ, Shattock RJ.

Hum Gene Ther. 2018 Sep;29(9):1011-1028. doi: 10.1089/hum.2018.075.

13.

Correction: Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies.

Torrone EA, Morrison CS, Chen PL, Kwok C, Francis SC, Hayes RJ, Looker KJ, McCormack S, McGrath N, van de Wijgert JHHM, Watson-Jones D, Low N, Gottlieb SL; STIMA Working Group.

PLoS Med. 2018 Jun 26;15(6):e1002608. doi: 10.1371/journal.pmed.1002608. eCollection 2018 Jun.

14.

The averted infections ratio: a novel measure of effectiveness of experimental HIV pre-exposure prophylaxis agents.

Dunn DT, Glidden DV, Stirrup OT, McCormack S.

Lancet HIV. 2018 Jun;5(6):e329-e334. doi: 10.1016/S2352-3018(18)30045-6. Review.

15.

Prevalence of sexually transmitted infections and bacterial vaginosis among women in sub-Saharan Africa: An individual participant data meta-analysis of 18 HIV prevention studies.

Torrone EA, Morrison CS, Chen PL, Kwok C, Francis SC, Hayes RJ, Looker KJ, McCormack S, McGrath N, van de Wijgert JHHM, Watson-Jones D, Low N, Gottlieb SL; STIMA Working Group.

PLoS Med. 2018 Feb 27;15(2):e1002511. doi: 10.1371/journal.pmed.1002511. eCollection 2018 Feb. Erratum in: PLoS Med. 2018 Jun 26;15(6):e1002608.

16.

Recent advances in pre-exposure prophylaxis for HIV.

Desai M, Field N, Grant R, McCormack S.

BMJ. 2017 Dec 11;359:j5011. doi: 10.1136/bmj.j5011. Review.

17.

How many MSM are taking PrEP: a service evaluation.

Whitlock GG, Douglas A, Adesara S, McCormack S, Nwokolo N, McOwan A.

Sex Transm Infect. 2017 Nov;93(7):529. doi: 10.1136/sextrans-2017-053315. No abstract available.

PMID:
29061697
18.

Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.

Cambiano V, Miners A, Dunn D, McCormack S, Ong KJ, Gill ON, Nardone A, Desai M, Field N, Hart G, Delpech V, Cairns G, Rodger A, Phillips AN.

Lancet Infect Dis. 2018 Jan;18(1):85-94. doi: 10.1016/S1473-3099(17)30540-6. Epub 2017 Oct 17.

19.

Perceived need of, and interest in, HIV pre-exposure prophylaxis amongst men who have sex with men attending three sexual health clinics in London, UK.

Bull L, Dimitrijevic P, Beverley S, Scarborough A, Mandalia S, Dosekun O, Barber T, Reeves I, McCormack S, Rayment M.

Int J STD AIDS. 2018 Apr;29(5):435-442. doi: 10.1177/0956462417730259. Epub 2017 Sep 20.

20.

Vaginal dysbiosis and pre-exposure prophylaxis efficacy.

van de Wijgert J, McCormack S.

Lancet HIV. 2017 Oct;4(10):e427-e429. doi: 10.1016/S2352-3018(17)30130-3. Epub 2017 Jul 18. No abstract available.

PMID:
28732774
21.

Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.

Bauer A, Podola L, Mann P, Missanga M, Haule A, Sudi L, Nilsson C, Kaluwa B, Lueer C, Mwakatima M, Munseri PJ, Maboko L, Robb ML, Tovanabutra S, Kijak G, Marovich M, McCormack S, Joseph S, Lyamuya E, Wahren B, Sandström E, Biberfeld G, Hoelscher M, Bakari M, Kroidl A, Geldmacher C.

J Virol. 2017 Aug 24;91(18). pii: e00730-17. doi: 10.1128/JVI.00730-17. Print 2017 Sep 15.

22.

Long-acting cabotegravir for prevention: hope versus reality.

McCormack S, Boffito M.

Lancet HIV. 2017 Aug;4(8):e322-e323. doi: 10.1016/S2352-3018(17)30074-7. Epub 2017 May 22. No abstract available.

PMID:
28546089
23.

Acceptability of an open-label wait-listed trial design: Experiences from the PROUD PrEP study.

Gafos M, Brodnicki E, Desai M, McCormack S, Nutland W, Wayal S, White E, Wood G, Barber T, Bell G, Clarke A, Dolling D, Dunn D, Fox J, Haddow L, Lacey C, Nardone A, Quinn K, Rae C, Reeves I, Rayment M, White D, Apea V, Ayap W, Dewsnap C, Collaco-Moraes Y, Schembri G, Sowunmi Y, Horne R; PROUD Study Team.

PLoS One. 2017 Apr 20;12(4):e0175596. doi: 10.1371/journal.pone.0175596. eCollection 2017.

24.

High HIV prevalence and incidence among women in Southern Mozambique: Evidence from the MDP microbicide feasibility study.

Mocumbi S, Gafos M, Munguambe K, Goodall R, McCormack S; Microbicides Development Programme.

PLoS One. 2017 Mar 28;12(3):e0173243. doi: 10.1371/journal.pone.0173243. eCollection 2017.

25.

Uptake of hormonal contraceptives and correlates of uptake in a phase III clinical trial in rural South Western Uganda.

Abaasa A, Gafos M, Anywaine Z, Nunn A, Crook A, Levin J, McCormack S, Kamali A.

Reprod Health. 2017 Mar 11;14(1):36. doi: 10.1186/s12978-017-0296-3.

26.

A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes.

Joseph S, Quinn K, Greenwood A, Cope AV, McKay PF, Hayes PJ, Kopycinski JT, Gilmour J, Miller AN, Geldmacher C, Nadai Y, Ahmed MI, Montefiori DC, Dally L, Bouliotis G, Lewis DJ, Tatoud R, Wagner R, Esteban M, Shattock RJ, McCormack S, Weber J.

Front Immunol. 2017 Feb 22;8:149. doi: 10.3389/fimmu.2017.00149. eCollection 2017.

27.

PrEP in Europe - expectations, opportunities and barriers.

McCormack SM, Noseda V, Molina JM.

J Int AIDS Soc. 2016 Oct 18;19(7(Suppl 6)):21103. doi: 10.7448/IAS.19.7.21103. eCollection 2016.

28.

Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities.

Girometti N, Jones R, Levy J, McCormack S, Sullivan A, Barber TJ.

AIDS. 2016 Aug 24;30(13):2131-3. doi: 10.1097/QAD.0000000000001171.

PMID:
27219131
29.

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.

Joachim A, Bauer A, Joseph S, Geldmacher C, Munseri PJ, Aboud S, Missanga M, Mann P, Wahren B, Ferrari G, Polonis VR, Robb ML, Weber J, Tatoud R, Maboko L, Hoelscher M, Lyamuya EF, Biberfeld G, Sandström E, Kroidl A, Bakari M, Nilsson C, McCormack S.

PLoS One. 2016 May 18;11(5):e0155702. doi: 10.1371/journal.pone.0155702. eCollection 2016.

30.

Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.

Cosgrove CA, Lacey CJ, Cope AV, Bartolf A, Morris G, Yan C, Baden S, Cole T, Carter D, Brodnicki E, Shen X, Joseph S, DeRosa SC, Peng L, Yu X, Ferrari G, Seaman M, Montefiori DC, Frahm N, Tomaras GD, Stöhr W, McCormack S, Shattock RJ.

PLoS One. 2016 May 9;11(5):e0152038. doi: 10.1371/journal.pone.0152038. eCollection 2016.

31.

HIV moments and pre-exposure prophylaxis--Authors' reply.

Dunn DT, Gafos M, White E, McCormack S.

Lancet. 2016 Apr 9;387(10027):1508. doi: 10.1016/S0140-6736(16)00695-4. Epub 2016 Apr 7. No abstract available. Erratum in: Lancet. 2016 Apr 23;387(10029):1722.

PMID:
27115971
32.

An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.

Dolling DI, Desai M, McOwan A, Gilson R, Clarke A, Fisher M, Schembri G, Sullivan AK, Mackie N, Reeves I, Portman M, Saunders J, Fox J, Bayley J, Brady M, Bowman C, Lacey CJ, Taylor S, White D, Antonucci S, Gafos M, McCormack S, Gill ON, Dunn DT, Nardone A; PROUD Study Group.

Trials. 2016 Mar 24;17:163. doi: 10.1186/s13063-016-1286-4.

33.

The role of progestins in HIV acquisition in young women.

Ramjee G, McCormack S.

Lancet Infect Dis. 2016 Apr;16(4):389-90. doi: 10.1016/S1473-3099(15)00476-4. Epub 2015 Dec 24. No abstract available.

PMID:
26723757
34.

Welcome to the preexposure prophylaxis revolution.

Baeten J, McCormack S.

Curr Opin HIV AIDS. 2016 Jan;11(1):1-2. doi: 10.1097/COH.0000000000000225. No abstract available.

PMID:
26633637
35.

The European preexposure prophylaxis revolution.

Cairns G, McCormack S, Molina JM.

Curr Opin HIV AIDS. 2016 Jan;11(1):74-9. doi: 10.1097/COH.0000000000000223. Review.

36.

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, Mackie N, Bowman C, Lacey CJ, Apea V, Brady M, Fox J, Taylor S, Antonucci S, Khoo SH, Rooney J, Nardone A, Fisher M, McOwan A, Phillips AN, Johnson AM, Gazzard B, Gill ON.

Lancet. 2016 Jan 2;387(10013):53-60. doi: 10.1016/S0140-6736(15)00056-2. Epub 2015 Sep 9.

37.

Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.

Munseri PJ, Kroidl A, Nilsson C, Joachim A, Geldmacher C, Mann P, Moshiro C, Aboud S, Lyamuya E, Maboko L, Missanga M, Kaluwa B, Mfinanga S, Podola L, Bauer A, Godoy-Ramirez K, Marovich M, Moss B, Hoelscher M, Gotch F, Stöhr W, Stout R, McCormack S, Wahren B, Mhalu F, Robb ML, Biberfeld G, Sandström E, Bakari M.

PLoS One. 2015 Apr 15;10(4):e0119629. doi: 10.1371/journal.pone.0119629. eCollection 2015.

38.

Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis.

Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, Van Damme L, Delany-Moretlwe S, Francis SC, Friedland BA, Hayes RJ, Heffron R, Kapiga S, Karim QA, Karpoff S, Kaul R, McClelland RS, McCormack S, McGrath N, Myer L, Rees H, van der Straten A, Watson-Jones D, van de Wijgert JH, Stalter R, Low N.

PLoS Med. 2015 Jan 22;12(1):e1001778. doi: 10.1371/journal.pmed.1001778. eCollection 2015 Jan.

39.

Communication About Microbicide Use Between Couples in KwaZulu-Natal, South Africa.

Gafos M, Pool R, Mzimela MA, Ndlovu HB, McCormack S, Elford J; MDP Team.

AIDS Behav. 2015 May;19(5):832-46. doi: 10.1007/s10461-014-0965-y.

40.

Biomedical prevention: state of the science.

McCormack SM, Gafos M, Desai M, Cohen MS.

Clin Infect Dis. 2014 Jul;59 Suppl 1:S41-6. doi: 10.1093/cid/ciu297.

41.

Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial.

Crook AM, Ford D, Gafos M, Hayes R, Kamali A, Kapiga S, Nunn A, Chisembele M, Ramjee G, Rees H, McCormack S.

Hum Reprod. 2014 Aug;29(8):1810-7. doi: 10.1093/humrep/deu113. Epub 2014 May 16.

42.

The implications of post-coital intravaginal cleansing for the introduction of vaginal microbicides in South Africa.

Gafos M, Pool R, Mzimela MA, Ndlovu HB, McCormack S, Elford J; MDP team.

AIDS Behav. 2014 Feb;18(2):297-310. doi: 10.1007/s10461-013-0676-9.

43.

Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.

Haire B, Folayan MO, Hankins C, Sugarman J, McCormack S, Ramjee G, Warren M.

Dev World Bioeth. 2013 Aug;13(2):87-94. doi: 10.1111/dewb.12032. Epub 2013 May 31.

44.

Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis.

Mayer K, Gazzard B, Zuniga JM, Amico KR, Anderson J, Azad Y, Cairns G, Dedes N, Duncombe C, Fidler SJ, Granich R, Horberg MA, McCormack S, Montaner JS, Rees H, Schackman B, Sow PS; International Association of Physicians in AIDS Care.

J Int Assoc Provid AIDS Care. 2013 May-Jun;12(3):208-16. doi: 10.1177/2325957413475839.

PMID:
23666450
45.

Microbicide clinical trial adherence: insights for introduction.

Woodsong C, MacQueen K, Amico KR, Friedland B, Gafos M, Mansoor L, Tolley E, McCormack S.

J Int AIDS Soc. 2013 Apr 8;16:18505. doi: 10.7448/IAS.16.1.18505. Review.

46.

Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort.

Ladep NG, Agaba PA, Agbaji O, Muazu A, Ugoagwu P, Imade G, Cooke G, McCormack S, Taylor-Robinson SD, Idoko J, Kanki P.

World J Gastroenterol. 2013 Mar 14;19(10):1602-10. doi: 10.3748/wjg.v19.i10.1602.

47.

Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda.

Abaasa A, Crook A, Gafos M, Anywaine Z, Levin J, Wandiembe S, Nanoo A, Nunn A, McCormack S, Hayes R, Kamali A.

Trials. 2013 Feb 1;14:33. doi: 10.1186/1745-6215-14-33.

48.

Audit of HIV testing frequency and behavioural interventions for men who have sex with men: policy and practice in sexual health clinics in England.

Desai M, Desai S, Sullivan AK, Mohabeer M, Mercey D, Kingston MA, Thng C, McCormack S, Gill ON, Nardone A; GUMNet.

Sex Transm Infect. 2013 Aug;89(5):404-8. doi: 10.1136/sextrans-2012-050679. Epub 2013 Jan 7.

PMID:
23300336
49.

Ethics, justice and community participation in the Microbicides Development Programme (MDP) Phase III trial in Mwanza, Tanzania.

Vallely A, Lees S, Shagi C, Kapiga S, McCormack S, Hayes R.

Am J Bioeth. 2012;12(11):46-8. doi: 10.1080/15265161.2012.719268. No abstract available.

PMID:
23072681
50.

The implementation and appraisal of a novel confirmatory HIV-1 testing algorithm in the Microbicides Development Programme 301 Trial (MDP301).

Jentsch U, Lunga P, Lacey C, Weber J, Cairns J, Pinheiro G, Joseph S, Stevens W, McCormack S.

PLoS One. 2012;7(9):e42322. doi: 10.1371/journal.pone.0042322. Epub 2012 Sep 11.

Supplemental Content

Loading ...
Support Center